Position in JANX
as of Jun 30, 2026
· filed Jul 10, 2026
Position Value
$791,377
+$79,850 QoQ
Shares Held
51,522
+0.7% QoQ
Ownership
0.084%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#3
of 12 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Tema ETFs LLC holds $116,572,434 across 52 Biotechnology names. JANX ranks #35 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
71,735 | $13,434,530 | |
| 2 | COGT |
Cogent Biosciences, Inc.
|
241,565 | $9,348,565 | |
| 3 | IMNM |
Immunome Inc.
|
268,167 | $5,682,458 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
76,076 | $5,666,140 | |
| 5 | EXEL |
Exelixis, Inc.
|
96,885 | $5,271,512 | |
| 6 | NUVL |
Nuvalent, Inc.
|
41,187 | $5,086,594 | |
| 7 | IDYA |
IDEAYA Biosciences, Inc.
|
135,847 | $5,063,017 | |
| 8 | CGON |
CG Oncology, Inc.
|
68,702 | $4,881,277 |
All Filings in JANX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $791,377 | 51,522 | Shares | Sole | 2026-07-10 | |
| 2026-03-31 | $711,527 | 51,189 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $511,869 | 37,092 | Shares | Sole | 2026-01-16 | |
| 2025-09-30 | $986,178 | 40,351 | Shares | Sole | 2025-10-24 | |
| 2025-06-30 | $1,156,501 | 50,065 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $1,240,299 | 45,937 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $279,639 | 5,223 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||